Purpose: Cancer immunotherapy, such as vaccination, is an increasingly successful treatment modality, but its interaction with chemotherapy remains largely undefined. Therefore, we explored the mechanism of synergy between vaccination with synthetic long peptides (SLP) of human papillomavirus type 16 (HPV16) and cisplatin in a preclinical tumor model for HPV16.
Introduction
Cancer immunotherapy based on the activation of the patient's own immune system, in particular T cells, has recently shown remarkable successes. Characteristically, clinical responses to active immunotherapy are often delayed compared with conventional debulking reagents (1) (2) (3) , begging the question whether fast-acting chemotherapeutics can be combined with immunotherapy. In several clinical trials, synergy between chemo-and immunotherapy was indeed observed (4, 5) . Some chemotherapeutic agents can induce immunogenic cell death, featuring release of proinflammatory factors from dying cells with the potential to mature dendritic cells (DC), thereby activating CD8 þ T cells (6) (7) (8) . In addition, chemotherapeutics can convert the tumor microenvironment into a site permissive for vaccination by enhancement of antigen density (9) . In about 50% of the patients with cervical cancer, the causative virus type is highrisk human papillomavirus type 16 (HPV16; ref. 10) . The two viral oncoproteins E6 and E7 are required for maintenance of the transformed cell state (11) , creating ideal targets for therapeutic vaccination (12) . Previous results from our group show that vaccination with synthetic long peptides (SLP) vaccines, directed against HPV16 E6 and E7, can effectively cause tumor regression in preclinical mouse tumor models and eradication of lesions caused by HPV16 in patients with premalignant disease (13) (14) (15) . Complete remission of grade 3 HPV16 þ vulvar intraepithelial neoplasia correlated with strong and broad SLP vaccineinduced T-cell immunity. However, in end-stage cervical cancer, this SLP vaccine causes less robust HPV-specific T-cell responses without an apparent effect on survival (16, 17) . We now show in preclinical models that therapeutic HPV16 E7 SLP vaccination has remarkable synergy with defined chemotherapeutic agents through mechanisms that are clearly distinct from those previously reported. The DNA cross-linking agent cisplatin displayed the strongest synergy with vaccination. The mechanisms of action are abundant infiltration with polyfunctional vaccine-induced CD8 T cells that synergize with cisplatin by tumor necrosis factor-a (TNFa)-mediated increased sensitivity of tumor cells to cisplatin-mediated killing, associated with reduced tumor cell proliferation after combination therapy. Notably, combination of therapeutic SLP vaccination with cisplatin leads to superior tumor eradication without added toxicity.
Materials and Methods
Mice Female C57BL/6 mice were purchased from Charles River Laboratories and housed in the animal facility of the Leiden University Medical Center (LUMC; Leiden, the Netherlands). The congenic strains Thy1.1 (CD90.1) and Ly5.1 (CD45.1) and ovalbumin-specific T-cell receptor (TCR) transgenic OT-I mice, all on a C57BL/6 background, were bred in house. All mice were housed in individually ventilated cage (IVC) systems under specific pathogen-free conditions and used at 8 to 10 weeks of age. Experiments were approved by the Animal Experiments Committee of the LUMC, in line with the guidelines of the European Committee.
Tumor cell lines and culture conditions
Tumor cell line TC-1 (a kind gift from T.C. Wu, John Hopkins University, Baltimore, MD) was generated by retroviral transduction of lung fibroblasts of C57BL/6 origin with HPV16 E6 and E7 and c-H-ras oncogenes (18) and maintained as previously described (14) . Tumor cell line C3 was generated by transfection of B6 mouse embryonic cells (MEC) with the complete HPV16 genome and maintained as previously described (19) . The methylcholanthrene-induced fibrosarcoma cell line MCA205 was kindly provided by Prof. T. T€ uting (University of Bonn, Germany). All cell lines were tested by PCR for rodent viruses with negative results. The DC line D1 was provided by P. Ricciardi-Castagnoli (University of Milano-Bicocca, Milan, Italy; ref. 20) . Human cervical adenocarcinoma cell line HeLa, human cervical carcinoma SiHa and MCA205 cells were cultured in RPMI-1640 (Gibco), supplemented with 8% FCS (Greiner), 100 IU/mL penicillin/streptomycin (Gibco), and 2 mmol/L glutamine (Gibco). Mycoplasma tests routinely performed for all cell lines by PCR were negative.
Tumor (-treatment) experiments
On day 0, C57BL/6 mice were subcutaneously inoculated with 1 Â 10 5 TC-1 tumor cells or 5 Â 10 5 C3 tumor cells in 200-mL PBS and 0.2% BSA. When a palpable tumor was present (day 8 for TC-1 experiments, day 14 for C3 experiments), mice were split into groups with comparable tumor size and were treated (intraperitoneal, i.p.) with chemotherapy. On the basis of the results with cisplatin, doses of chemotherapy used were similar to the reported maximal-tolerated dose (MTD), but provided in a split dose with an interval of 1 week, resulting in the following doses: cisplatin (10 and 4 mg/kg), doxorubicin (4 mg/kg), oxaliplatin (5 mg/kg), gemcitabine (100 mg/kg), carboplatin (40 mg/kg), paclitaxel (20 mg/kg) at day 8 and 9, or with topotecan (2 mg/kg) at days 8, 9, 10, and 11. At the same time of the first chemotherapy treatment, mice with and without chemotherapy were vaccinated in the contralateral flank with synthetic long HPV16 E7 peptide (GQAEPDRAHY-NIVTFCCKCDSTLRLCVQSTHVDIR), dissolved in PBS and emulsified in Montanide ISA 51 on day 9 upon tumor challenge or with 4 mg/kg cisplatin in NaCl i.p. on day 15 upon tumor challenge or with the combination (Fig. 1A) .
In vivo antibody treatment
For in vivo CD4 þ and CD8 þ T-cell depletion, mice were injected i.p. on day 7 and then every 6 days onward with 100 mg of the monoclonal antibodies (mAbs) GK1.5 and YTS-169, respectively. All mice used had a >99% depletion of
Translational Relevance
Previously, we have shown that synthetic long peptides (SLP) vaccination against human papillomavirus type 16 (HPV16) oncogenic proteins is safe and induces functional T-cell responses in mice and humans. Although vaccination induces potent clinical responses in mice and in patients with premalignant lesions, no clinical responses were observed in patients with cervical cancer. Here, we show that SLP vaccination can be safely combined with seven relevant chemotherapeutics without hampering the vaccine-induced antitumor response. In fact, vaccination synergizes strongly with cisplatin, without being dependent on the maximum-tolerated dose (MTD), thereby reducing toxicity. SLP vaccination induces tumor infiltration of tumor necrosis factor-a (TNFa) and interferon-g (IFNg)-producing T cells. Of these cytokines, TNFa was able to sensitize several mouse and human tumor cell lines for cisplatin-mediated killing. In vivo neutralization of TNFa strongly decreases the synergistic antitumor effect of cisplatin with peptide vaccination, indicating the crucial role of TNFa in tumor eradication. Our study indicates that vaccine-induced entry of TNFa-producing T cells into the tumor significantly enhances the tumoricidal effects of chemotherapy without requirement for the MTD. the targeted T-cell population as measured by flow cytometry. For in vivo TNFa neutralization, mice were injected i.p. on day 7 and then twice weekly until day 23 with 450 mg of mAb MP6-XT22. mAbs were prepared and purified as described previously (21) .
Adoptive transfer experiments
For adoptive transfers, 0. Furthermore, single-cell suspensions of tumor(-infiltrate) were incubated for 5 hours with 40,000 D1 cells preloaded with the SLP HPV16 E7 (10 mg/mL) in the presence of Brefeldin A (2 mg/mL) after which an intracellular cytokine staining was performed.
Microscopy
Isolated tumors from transcardially perfused mice were embedded in Tissue-Tek and immediately frozen in 2-methylbutane cooled on dry ice. Cryostat sections (4-5 mm) were cut at À20 C, dried overnight at 60 C, and then frozen at À20 C.
After thawing, samples were fixed with acetone, dried, washed in PBS, incubated with biotinylated CD4 mAb (clone RM4-5; Pharmingen), washed and stained with CD3 mAb (Alexa Fluor 647, clone 17A2; BioLegend) and streptavidin Alexa Fluor 546 (molecular probes) in PBS with mouse serum. Images (Â200) were captured with a confocal laser scanning microscope (Zeiss LSM 510). For analysis of mitosis activity, slides were stained with hematoxylin and eosin (H&E). Cell-and mitosis-counts were scored by two independent investigators. In vivo apoptosis was analyzed on cryostat sections by the use of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technology (in situ cell death detection kit, POD; Roche) according to the manufacturer's instructions. TUNEL staining was visualized with the substrate DAB (3,3 0 -diaminobenzidine tetrahydrochloride) after which the samples were counterstained with hematoxylin (Dako). Tissue sections treated without TdT were used as negative control.
CTL assay
Tumor-free C57BL/6 mice were immunized with synthetic HPV16 E7 peptide and 20 mg CpG. Eight days after boosting, splenocytes were isolated, restimulated with the specific peptide for 7 days, and used as effectors in a CTL assay against TC-1 target cells. Interferon-g (IFNg; Prospec) exposed or nonexposed TC-1 tumor cells were incubated with various concentrations of cisplatin and incubated overnight. The next day, cells were washed, incubated for 1 hour with 1 mg/mL of E7 peptide (RAHYNIVTF), and then used in a 4-hour 51 Cr release assay. Target cells were then labeled with 100 mL 51 Cr for 1 hour, washed, and plated into a 96-well round-bottomed plate at a density of 2,000 tumor cells per well together with T cells (of which 4% was E7-specific as measured by tetramer staining) at the indicated E:T ratios. After 4 hours, cells were harvested, and the percentage 51 Cr release was measured using a gamma counter.
Cell viability assays
For the various assays, TC-1 was seeded at 8,000 cells per well with 20 ng (250 international units) mouse TNFa (Prospec) and 2 mg/mL cisplatin. Concentrations of topotecan, carboplatin, and paclitaxel are indicated in Supplementary Figure S4F . C3 was seeded at 10,000 cells per well with 4 ng/mL TNFa and 6 mg/mL cisplatin, MCA205 was seeded at 7,000 cells per well with TNFa and cisplatin (concentrations are indicated in Supplementary Figure S4D ). HeLa cells were plated at 18,000 cells per well with 2 mg/mL cisplatin and 25 ng/mL hTNFa, 40 mg/mL etanercept (Enbrel), or supernatant of phytohemagglutinin (PHA; 0.5 mg/mL)-stimulated peripheral blood mononuclear cells (PBMCs) of a healthy donor. SiHa cells were seeded at 20,000 cells per well with 100 ng/mL TNFa and 12 mg/mL cisplatin. Realtime apoptosis induction was quantified using a live cell apoptosis assay as previously described (23) . Briefly, tumor cells were seeded into a GreinerBioOne 96-wells uClear plate and incubated for 24 hours. Then, cisplatin and/or TNFa were added to the cells. Binding of Annexin V-Cy3 conjugate to phosphatidyl serine present on the membranes of apoptotic cells was quantified in time by imaging with a BD Pathway 855 imager (Becton Dickinson). The total area of Annexin V-Cy3 fluorescence per image was quantified using Image Pro (Media Cybernetics). Cell death induced by cisplatin with supernatant of peptide-treated tumors was analyzed by Annexin V staining using flow cytometry.
Cell viability was determined using a standard colorimetric MTT (3-4,5-dimethylthiazol-2-yl-2, 5-diphenyl-tetrazolium bromide) reduction assay (Trevigen) and performed via the setup used for the live cell apoptosis assay. Analysis was performed 22 hours after cisplatin and/or TNFa exposure. Control cells without agents were cultured in parallel using the same conditions with comparable media changes. Absorbance was measured with a microplate reader (Bio-Rad) at a test wavelength of 570 nm, and a reference wavelength of 655 nm. For each treatment, cell viability was evaluated as a percentage using the following equation: (OD of treated sample/mean OD of untreated sample) Â 100.
Quantitative real-time PCR
TC-1 tumor cells were harvested and then seeded at 1.3 Â 10 5 cells per well (6 wells plate). After 24 hours of incubation, TNFa and/or cisplatin were added. Twenty-four hours later, cells were harvested and suspended in TRizol. Total RNA was isolated from cells using an RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. cDNA was synthesized using SuperScript III Reverse Transcriptase (Invitrogen). Oligonucleotide primers are compiled in Table 1 . Reactions were performed using iQ SybrGreen supermix (Bio-Rad) on the my-iQ Real-Time PCR (BioRad) with an annealing temperature of 60 C. Cycle threshold (C t ) values were normalized to the expression levels of the GAPDH and b-actin genes.
Statistical analysis
Survival for differentially treated mice was compared using the Kaplan-Meier method and the log-rank (Mantel-Cox) test. Additional statistical methods are stated in the legends. All P < 0.05 were considered significant.
Results

Cisplatin displays the strongest synergy with SLP vaccination
To test which chemotherapeutics have favorable antitumor effects in combination with therapeutic SLP vaccination, the HPV16 SLP vaccine was combined with seven clinically relevant chemotherapeutic agents. Mice were inoculated with TC-1 tumor cells, expressing the HPV16 oncoproteins E6 and E7, and tumor size was longitudinally measured. When a palpable tumor was present on day 8 after tumor challenge, treatment was started. Systemic treatment with chemotherapeutic agents alone, given twice with a 1-week interval (Fig. 1A) , displayed a modest transient effect on tumor outgrowth (Fig. 1B-D Supplementary Fig. S1A ). In particular, cisplatin synergized well with SLP vaccination, resulting in a survival of 75% to 80% of the mice. To avoid significant weight loss ( Supplementary Fig. S1B ), a lower, less toxic, dose of cisplatin was used. Similar to the higher dose, the lower cisplatin dose combined with peptide vaccination completely eradicated tumors in approximately 75% of the mice ( Fig. 1D and Supplementary Fig. S1B ). There was indeed no significant difference between these two groups of chemo-immunotherapy-treated mice (P ¼ 0.47), emphasizing the fact that in combination with immunotherapy, dosing of chemotherapy can be lower, avoiding unnecessary toxicity such as weight loss. Mice successfully treated with this combination remained tumor free for at least 2 months. When such tumorfree mice were rechallenged with TC-1 tumor cells, all were protected (data not shown). In a different murine tumor model for cervical cancer, a transformed B6 MEC line with the complete HPV16 genome (C3), the combined SLP, and cisplatin treatment again resulted in a stronger decrease in tumor size than single treatment ( Supplementary Fig. S1C ). Of note, after day 32, many of the shrunken C3 tumors grew out again, possibly via immuneescape.
In TC-1 tumor-bearing mice treated with both cisplatin and SLP vaccination, we observed that while elimination of CD4 þ T cells had no effect on treatment efficacy, CD8 þ T cell depletion completely abolished tumor control by the combined treatment ( Supplementary Fig. S1D ). Together, these data show that clinically relevant chemotherapy can be safely combined with SLP vaccination. We selected the effective and nontoxic combination with lower dose cisplatin to further investigate the mechanisms of synergy.
Effect of cisplatin chemotherapy on T-cell numbers, function, and homing capacity To understand the mechanisms underlying the synergy observed with cisplatin plus SLP vaccination, we first asked whether chemotherapy can affect the antigen-specific expansion and differentiation of T cells. To this end, mice were injected i.v. with OT-I and OT-II TCR transgenic T cells. On this same day, these mice were vaccinated with two SLPs comprising the T-cell epitopes recognized by OT-I and OT-II T cells, emulsified with Montanide ( Fig. 2A) . Treatment with gemcitabine, carboplatin, or cisplatin did not affect either the numbers of OT-I/OT-II T cells or their cytokine production at the doses tested ( Fig. 2B-E , and not shown).
Similar results were found in experiments in which the endogenous vaccine-induced HPV16-specific T-cell response in TC-1 tumor-bearing mice was measured. The percentages of circulating HPV16-specific tetramer-positive CD8 þ T cells in mice vaccinated with SLP alone were comparable with those in mice treated with SLP vaccination and cisplatin ( Fig. 2F and G) . In addition, expression of the activation molecules CD25, CD69, CD137, and KLRG1 appeared unaffected on both CD4 þ and CD8 þ T cells, at least for cisplatin treatment (Supplementary Fig. S2 ).
To explore whether cisplatin-exposed T cells have differential homing capacity to the tumor microenvironment compared with unexposed T cells, adoptive transfers of congenically marked endogenous T cells from tumor-bearing mice, treated with SLP vaccine (Ly5.1) or with SLP vaccine and cisplatin (Thy1.1), were transferred into the same, CD8
þ T cell-depleted host mice (Thy1.2/Ly5.2). Eight days later, spleens, LNs, and tumors were harvested and the presence of adoptively transferred cells was analyzed, revealing that cisplatin-exposed T cells were equally efficient in repopulating the spleen, LNs, and tumor as nonexposed T cells (Fig. 2H ). Taken together, we conclude that the synergy observed between some chemotherapeutic agents and vaccination is not related to overt changes in systemic T-cell immunity.
Vaccination strongly increases the number of intratumoral polyfunctional CTLs Next, we focused on effects of combined chemo-immunotherapy on the tumor microenvironment. Tumor size significantly affects various immune parameters (24, 25) . Therefore, we used a treatment protocol (Fig. 3A) in which cotreatment still effectively synergized ( Supplementary Fig. S3 ), but analyzed the tumors at the start of the regression phase (Fig.  3B) . Analysis of the immune infiltrate in the tumor microenvironment at the start of regression showed that the percentage of leukocytes significantly increased upon treatment with cisplatin, peptide, and the combined treatment. The combination treatment resulted in a total of approximately 60% leukocytes in the tumor environment on day 19 ( Fig. 3C and D) . Given the significant tumor regression observed upon combined treatment, enhanced leukocyte infiltration at later time points is expected but has not been tested.
Although cisplatin was capable of inducing CD45 þ leukocyte infiltration, very few of these cells were CD8 þ T cells (Fig. 4A-F) . Interestingly, substantial numbers of CD8 T cells were entering the tumor upon peptide vaccination or the combination treatment (7.8 times more CD8 þ T cells in the combined treatment group compared with untreated; Fig. 4A ). Confocal microscopy using antibodies to CD4 (red) and CD3 (blue) confirmed our observation that vaccination Further characterization of the tumor-infiltrating CD8 þ T-cell population revealed a high expression of Ki-67 (Fig. 4D) as a marker of proliferation, and showed that a very high percentage 
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** ** ** ** ($40%) specifically recognized the tumor antigen E7 (Fig. 4E ). When isolated, many of the tumor-infiltrating T cells produced the proinflammatory cytokines IFNg and TNFa after in vitro exposure to E7-presenting antigen-presenting cells (D1 cell line; Fig. 4F ). Together, these data show that although chemotherapy and vaccination can both enhance leukocyte infiltration of the tumors, IFNg-and TNFa-producing antigen-specific CD8 T cells enter this tumor only upon specific vaccination. Because cisplatin addition to vaccination had no effect on these CD8 T cells, we hypothesized that the enhanced antitumor responses observed upon combined treatment were not due to direct effects on the tumoricidal CD8 T cells but rather due to differences in the tumor cells.
Combined treatment of vaccination with cisplatin decreases tumor cell proliferation
While the intratumoral T cells expressed high levels of Ki-67, we noticed that the Ki-67 levels in tumor cells of the combined treatment group were considerably lower than in tumor cells from untreated, cisplatin-, or peptide-treated mice, suggesting a decrease in tumor cell proliferation caused by the combined interaction of cisplatin and peptide (Fig. 5A) . To corroborate this, the numbers of mitotic figures per high-power field in H&E-stained sections, a well-reproducible, strong prognosticator of disease in LN-negative patients (26) , were compared between the untreated group and the various treatment groups. This analysis confirmed that upon either cisplatin or peptide vaccination alone, A, single-cell suspensions of 6 mice per group were stained for CD45, fixed, permeabilized, and stained for Ki-67. Representative flow cytometry plots for untreated mice and peptide plus cisplatin-treated mice (left), Ki-67 expression quantification (right). Data are analyzed by one-way ANOVA and expressed as mean with SEM. B, H&E-stained tumor sections were scored for mitotic activity. A representative photo from a nontreated tumor containing instances of mitotic activity (left) and mitotic activity scores in all indicated treatment groups (right). Four fields per section were scored for mitotic activity. Data indicate the average scores for 4 mice per group. Similar results were obtained in another independent experiment. Data are analyzed by ordinary one-way ANOVA followed by Tukey post hoc analysis ( Ã , P < 0.05; ÃÃ , P < 0.01). Vaccinated : cisplatin 1 μg/mL Naïve: cisplatin 0 μg/mL the division rate of tumor cells declined but the lowest number of mitoses was observed upon combined cisplatin and vaccination treatment (Fig. 5B) . Following in vitro treatment of tumor cells with TNFa, IFNg, and/or cisplatin, both Ki-67 and proliferating cell nuclear antigen (PCNA) levels were not decreased (data not shown), suggesting that the decreased proliferation of tumor cells is not a result of direct exposure to either one of these T cellproduced cytokines. Together, these data show that combined cisplatin and SLP vaccination decrease the proliferation of tumor cells more extensively in vivo than either treatment alone.
Combined treatment of vaccination with cisplatin enhances tumor cell death and is caused by the combined action of TNFa and cisplatin Tumor regression and clearance ultimately depend on tumor cell death. We therefore analyzed in vivo cell death by the TUNEL assay, a technique that detects fragmented DNA resulting from apoptosis. Strikingly, we observed that the combination treatment significantly enhanced tumor cell death compared with the untreated and cisplatin-treated tumors on day 17 already (Supplementary Fig. S4A ) and also on day 19 ( Fig. 6A and B) .
First, we hypothesized that cisplatin might enhance the susceptibility of tumor cells to T-cell killing. To test this, TC-1 tumor cells were pretreated with various doses of cisplatin. The highest dose induced approximately 40% cell death and the lowest dose almost no cell death as measured by the MTT assays (data not shown). After washing, the tumor cells were incubated with splenocytes containing 4% HPV16-specific CD8 þ T cells (data not shown). Although tumor cells were efficiently killed by these splenocytes in these short cytotoxicity assays, cisplatin pretreatment did not enhance sensitivity toward CTL-mediated killing (Fig. 6C) . Thus, the observed synergy between SLP vaccination and cisplatin cannot be explained by an increased sensitivity of cisplatin-treated TC-1 tumor cells toward CTL-mediated killing as measured by short chromium release assays. Therefore, we hypothesized that the enhanced killing of tumor cells observed in vivo rather depends on prolonged and sustained cooperation between T-cell effector function and cisplatin activities on tumor cells. Because we have seen that tumors from vaccinated mice are highly infiltrated with IFNg-and TNFa-producing T cells, we hypothesized that the synergistic effect on tumor cell death was due to an enhancement of cisplatin-induced cell death by these cytokines. We therefore examined the effect of IFNg and TNFa on cisplatin-induced tumor cell death. By live apoptosis imaging, it became apparent that coincubation of cisplatin with various dosages of IFNg had no effect on cell death (Fig. 6D and data  not shown) . Strikingly, TNFa exposure strongly sensitized tumor cells to cisplatin-mediated killing ( Fig. 6D; Supplementary Fig.  S4B ; Supplementary Movies S1-S4). This observation was confirmed by performing an MTT assay with recombinant TNFa (Fig.  6E) , and supernatant of overnight incubated single-cell suspensions of peptide-treated tumors (Supplementary Fig. S4C ).
To test whether TNFa sensitization of cisplatin-treated tumor cells is a general phenomenon, similar experiments were done with mouse tumor cell lines C3 and MCA 205 and human cervical cancer cell lines SiHa and HeLa, yielding comparable results ( Fig.  6F and Supplementary Fig. S4D and S4E) . Similarly, the supernatant of activated PBMCs could sensitize HeLa tumor cells for cisplatin-induced killing ( Supplementary Fig. S4E and Fig. 6G ). Because the addition of the TNFa inhibitor etanercept fully abolished this synergy (Fig. 6G) , we concluded that specifically the TNFa in the supernatant of these human T cells sensitized for cisplatin cell death. In addition, we observed that TNFa could sensitize tumor cells for topotecan-and carboplatin-induced tumor cell death but not for paclitaxel-induced apoptosis (Supplementary Fig. S4G ).
Enhanced cell death of TC-1 cells was accompanied by a TNFainduced upregulation of the antiapoptotic molecule c-IAP2, and a cisplatin-induced upregulation of the proapoptotic gene Xaf1. Remarkably, treatment with both cisplatin and TNFa strongly enhanced expression of the proapoptotic molecule Bfk, suggesting a crucial role for this molecule in the observed synergy (Fig.  6H) . Expression of the antiapoptotic molecules Bruce and Bcl-xL was not altered by TNFa, cisplatin, or combined exposure (data not shown).
TNFa binding to TNFR1 and TNFR2 can induce signaling leading to either cell survival or cell death. The activation status of the MAPK family member JNK determines cellular outcome (27) . In addition, it has been found that combined cisplatin/TNFa treatment of renal proximal tubular cells induces JNK activation, Cr-release CTL assay against IFNg pretreated TC-1 target cells. Four percent of the effectors were E7-specific (as determined by tetramer staining). TC-1 target cells were treated overnight with indicated doses cisplatin and then extensively washed. As a control T cells from na€ ve mice were used. Data represent nine individual experiments. D, TC-1 cells were in vitro exposed to cisplatin, IFNg, and TNFa. Cell death was followed over time using Annexin V staining and automated imaging on a BD pathway 855 imager (left). Still images of time laps movies were taken at 22 hours after cisplatin and TNFa addition (right). E, dose response of TC-1 cell survival upon exposure to cisplatin in the presence (blue) or absence (red) of TNFa as measured by the MTT assay. Representative result of five independent experiments. F, Annexin V staining for tumor cells C3, HeLa, and SiHa exposed in vitro to TNFa and cisplatin. G, HeLa cells were in vitro exposed to 2 mg/mL cisplatin, 60% supernatant of PHA-stimulated PBMCs of a healthy donor, and the TNFa inhibitor etanercept (40 mg/mL). The amount of viable cells was analyzed by the MTT assay. Data shown are representative for three individual experiments. H, gene expression of the proapoptotic genes Bfk and Xaf1 and the antiapoptotic gene c-IAP2 in TC-1 cells 22 hours after exposure to cisplatin and TNFa, represented as fold change over untreated TC-1 cells. Representative for three independent experiments. I, TC-1 cells were incubated with 40 mmol/L of the JNK-specific inhibitor SP600125, 30 minutes before cisplatin/TNFa treatment and cell death was measured by Annexin V staining and automated imaging on a BD pathway 855 imager. Representative for three independent experiments. J, wild-type C57BL/6 mice were injected s.c. with TC-1 tumor cells in the flank. From day 7 and onward, mice received TNFa-neutralizing antibodies via i.p. injection. On day 8, when tumors were palpable, mice were treated systemically with cisplatin and/or HPV16 E743-77 peptide in Montanide in the opposing flank. Chemotherapy was repeated 1 week after initial treatment and vaccination was repeated 2 weeks after initial treatment. Shown is a Kaplan-Meier survival plot for chemo(immune-) therapy with TNF-neutralizing antibodies. Significance and number of mice per group are indicated ( Ã , P < 0.05; ÃÃ , P < 0.01).
leading to a shift in apoptotic programming and, causing tubular cell apoptosis at much lower cisplatin levels than in the absence of TNFa (28) . We hypothesized that a similar mechanism may play a role in the synergy between vaccine-induced T-cell responses and cisplatin treatment. When TC-1 tumor cells were pretreated with the JNK inhibitor SP600125, cisplatin-TNFa-induced cell death was largely inhibited (Fig. 6I) , indicating that JNK activation is important in the TNFa-mediated sensitization of tumor cells to cisplatin-induced killing. Next, we used TNFa-neutralizing antibodies to examine the role for TNFa in the synergy between cisplatin and peptide vaccination observed in vivo. Strikingly, the use of TNFa-neutralizing antibodies strongly decreased the synergy between cisplatin and peptide vaccination (Fig. 6J) . Together, these data show that TNFa sensitizes for cisplatin in a JNK-dependent manner causing synergistic cell death. This is confirmed by the observation that tumors from the combined treatment group contain significantly more apoptotic tumor cells than tumors from single-treated mice. Moreover, we show that vaccination induces TNFa-producing T cells in the tumor. When the mice, treated with peptide vaccination and cisplatin, receive TNFa-neutralizing antibodies, the synergy between the two treatments is strongly decreased, emphasizing the important role for TNFa in the cisplatin þ peptide-induced antitumor response.
Discussion
In this study, we show that SLP vaccination combined with clinically relevant chemotherapeutic agents acts synergistically in tumor eradication. Combined treatment of low-dose cisplatin with peptide significantly enhanced survival compared with single treatment with high-dose cisplatin. Effective antitumor responses induced by the combined treatment were accompanied by enhanced leukocyte infiltration into the tumor, in particular by vaccine-specific CD8 þ T cells. Because our vaccination protocol includes subcutaneous antigen delivery in Montanide in the opposing flank, T cells must have been actively attracted to the contralateral tumor site. In the local tumor environment, these T cells produce TNFa and IFNg, indicating that they are fully functional. Reportedly, TNFa and IFNg can drive cancer cells into senescence, corresponding to a decreased Ki-67 expression (29) . Although the cisplatin-treated TC-1 tumors infiltrated with vaccine-induced TNFa-and IFNg-producing T cells show a decreased proliferation in vivo, in vitro treatment of tumor cells with TNFa, IFNg, and/or cisplatin was not associated with decreased Ki-67 and PCNA levels (measured by qPCR, data not shown). This suggests that, at the doses used, TC-1 tumor cells were not driven into senescence by TNFa and IFNg. The two HPV16 oncoproteins E6 and E7 are expressed by TC-1 tumors (18) . A recent study on mouse keratinocytes reported that the oncoprotein E7 can interfere with IFNg-mediated JAK1-JAK2-STAT1-IRF-1 signaling pathways (30) . Because STAT1-deficient b-cancer cells resisted TNFa-and IFNg-induced senescence (29), we hypothesize that E7 expression by TC-1 tumor cells protects them from complete senescence.
Over one third of patients treated with cisplatin develop renal injury within 10 days after a single dose of cisplatin. A molecule strongly associated with cisplatin-induced (nephro-) toxicity is TNFa (28, (31) (32) (33) . Although this cytokine has been proposed as a strong trigger of cancer cell death (34) , its life-threatening toxicity when administered systemically prohibits systemic clinical use (31, 35) . Intratumoral administration of TNFa remains challenging for some primary tumors and especially for metastasis. In contrast to renal parenchymal cells (36) , TC-1 tumor cells did not express TNFa after cisplatin treatment (data not shown). Strikingly, we show here that SLP vaccination induces large numbers of TNFa-producing T cells that are likely further stimulated to produce TNFa by antigen encounter within the tumor. In turn, this allows synergistic cell death of tumor cells when combined with cisplatin (Fig. 6) , and other (carboplatin and topotecan) but not all chemotherapeutics. Previously, it was observed that HPV16 E7-specific immune responses combined with cisplatin treatment can enhance apoptotic tumor cell death (37, 38) . Here, we confirm these observations and additionally show that TNFa has a key function in this enhanced cell death, indicated by the decreased synergy between cisplatin and vaccination in antitumor responses when TNFa was neutralized by systemic antibody treatment. Also, incubation of tumor cells with TNFa combined with low doses of cisplatin can enhance proapoptotic molecule expression in tumor cells and thus increases the level of cell death. Because cisplatin with TNFamediated apoptosis is induced after a minimum of 10 hours, this mechanism is likely not involved in short in vitro cytotoxicity assays as performed us (Fig. 6C ) and others (37, 39) . However, the synergy is relevant when TNFa-producing T cells and cisplatin are together with tumor cells for a longer period as occurs in the in vivo situation.
In addition to the previously described chemotherapyenhanced sensitivity for granzyme B-mediated tumor cell death by intratumoral T cells (39, 40) , the synergy between TNFa and cisplatin is a novel mechanism involved in successful chemoimmunotherapy. We postulate that both mechanisms can be involved in previous studies in which synergy was observed between cisplatin and efficient T cell-based immunotherapy (9, 37, 38, (41) (42) (43) (44) .
In addition to cisplatin-induced cell death, TNFa can enhance doxorubicin-induced apoptosis (45) . However, it was recently shown that although doxorubicin enhances the RNA levels of TNFa by tumor cells, this cytokine is not involved in doxorubicin-induced antitumor responses in various tumor models (46) . The levels of TNFa induced by the vaccine-induced CD8 þ T-cell infiltrated in the tumor beds are likely to be much higher than the levels produced by chemotherapy-treated tumors, explaining why these T cells can potentiate cisplatinmediated apoptosis, resulting in the remarkable synergistic antitumor activity of cisplatin and SLP vaccination seen in the current work. These data show that the introduction of different forms of active T cell-based immunotherapies into clinical practice calls for detailed analyses of the different forms of chemotherapy that best synergize with and support the immunotherapy. What is a scourge in the toxicity of cisplatin toward kidney tubular epithelial cells (28, 36) turns out to be a blessing in the enhanced demise of tumor cells helped along by the locally high levels of TNFa produced by vaccine-induced tumorspecific T cells. Other investigators have shown marked differences in the induction of immunogenic cell death by different chemotherapeutic compounds (47) . This is obviously of major importance in the absence of additional robust stimulation of tumor-specific Tcell responses, such as possible by SLP vaccination. In the case of this study, induction of a therapeutic T-cell immune response by chemotherapy itself is of no major consequence, because of the robust SLP vaccine that is capable of inducing a powerful therapeutic immune response by itself. Upon vaccination combined with cisplatin, the tumor microenvironment is highly infiltrated with leukocytes, including the HPV-specific, cytokine-producing, tumoricidal T cells. This work shows that together with TNFa produced by the abundant T cells in the tumor, cisplatin enhances cell death and causes decreased proliferation of tumor cells. These data elucidate mechanisms by which therapeutic vaccination synergizes with cisplatin for efficient systemic antitumor T-cell responses, providing a strong rationale for implementation of this type of chemo-immunotherapy. 
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